PER — Percheron Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- AU$6.09m
- AU$2.07m
- AU$0.15m
Annual balance sheet for Percheron Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 19.2 | 11 | 11.9 | 10.2 | 4.05 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.84 | 1.66 | 2.57 | 1.58 | 0.962 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 22.2 | 12.7 | 14.5 | 12.4 | 5.29 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.217 | 0.151 | 0.057 | 0.035 | 0.038 |
| Net Intangible Assets | |||||
| Total Assets | 22.4 | 12.8 | 14.5 | 12.4 | 8.22 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.16 | 2.81 | 5.15 | 2.43 | 0.692 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.3 | 2.87 | 5.17 | 2.43 | 0.692 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 21.1 | 9.98 | 9.36 | 10 | 7.53 |
| Total Liabilities & Shareholders' Equity | 22.4 | 12.8 | 14.5 | 12.4 | 8.22 |
| Total Common Shares Outstanding |